Sarepta (SRPT) Bullish View Reiterated at Credit Suisse at EXONDYS51 Gains Momentum
Tweet Send to a Friend
Credit Suisse analyst Alethia Young reiterated an Outperform rating and $64 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
